Acutaas Chemicals' subsidiary has sold a 10% stake to A.R.Z Pharma, resulting in a decrease of parent company ownership to 90%. However, the management control over the subsidiary remains unaffected by this transaction.

Acutaas Chemicals emphasizes growth across pharmaceuticals, specialty chemicals, semiconductors, and battery chemicals in their investor presentations. They currently boast a 1,100 KL manufacturing capacity in South Korea, with plans for expansion in the region.

Acutaas Chemicals aims for a 25% revenue increase next fiscal year by expanding its research and development efforts, with plans to strategically shift its product portfolio for growth. [ScoutQuest]

Acutaas Chemicals plans to increase its revenue by 25% in the fiscal year 2027 compared to the previous year, aiming to surpass the 33% growth achieved in FY26. The company's managing director is optimistic about meeting this target for the upcoming fiscal year.

Acutaas Chemicals reports a significant 40% year-on-year increase in Q4 revenue, reaching an impressive ₹4.2 billion – indicative of strong growth.

Acutaas Chemicals announces a final dividend of INR 2.5 per share, providing shareholders with the opportunity to receive a cash payout for the current period.

Acutaas Chemicals has announced a board meeting on April 30, 2026, to discuss and approve the Q4 and annual financial results for the fiscal year 2025-26. The meeting will also cover the final dividend recommendation and other business matters. Trading in Acutaas shares will remain suspended until May 2, 2026.